Back to Browse Journals » Vascular Health and Risk Management » Volume 9

Linagliptin as add-on therapy to insulin for patients with type 2 diabetes

Authors von Websky K, Reichetzeder C, Hocher B

Published Date November 2013 Volume 2013:9 Pages 681—694

DOI http://dx.doi.org/10.2147/VHRM.S40035

Received 8 August 2013, Accepted 24 September 2013, Published 1 November 2013

Karoline von Websky, Christoph Reichetzeder, Berthold Hocher

Institute of Nutritional Science, University of Potsdam, Potsdam-Rehbrücke, Germany

Abstract: Type 2 diabetes mellitus (T2DM) is a highly prevalent, progressive disease that often is poorly controlled. The combination of an incretin-based therapy and insulin is a promising approach to optimize the management of glycemic control without hypoglycemia and weight gain. Linagliptin, a recently approved oral dipeptidyl peptidase-4 inhibitor, has a unique pharmacological profile. The convenient, once-daily dosing does not need adjustment in patients with hepatic and/or renal impairment. In clinical studies linagliptin shows an important reduction of blood glucose with an overall safety profile similar to that of placebo. So far, the combination of linagliptin and insulin has been tested in three major clinical studies in different populations. It has been shown that linagliptin is an effective and safe add-on therapy to insulin in patients with T2DM. The efficacy and safety of this combination was also shown in vulnerable, elderly T2DM patients and in patients with T2DM and renal impairment. Favorable effects regarding the counteraction of hypoglycemia make linagliptin especially interesting as an add-on therapy to insulin. This review aims to present the existing clinical studies on the efficacy and safety of linagliptin as add-on therapy to insulin in patients with T2DM in the context of current literature. Additionally, the possible advantages of linagliptin as an add-on therapy to insulin in relation to cardiovascular safety, patient-centered therapy and the prevention of hypoglycemia, are discussed.

Keywords: incretin, dipeptidyl peptidase-4, glucagon like peptide-1, glycemic control, renal impairment, hypoglycemia

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Surgical outcomes in phacoemulsification after application of a risk stratification system

Tsinopoulos IT, Lamprogiannis LP, Tsaousis KT, Mataftsi A, Symeonidis C, Chalvatzis NT, Dimitrakos SA

Clinical Ophthalmology 2013, 7:895-899

Published Date: 16 May 2013

Relationship between interblink interval and dopamine

Lemon TI, Shah RD

Clinical Ophthalmology 2013, 7:793-794

Published Date: 29 April 2013

Pluronic mixed micelles overcoming methotrexate multidrug resistance: in vitro and in vivo evaluation

Chen Y, Sha X, Zhang W, Zhong W, Fan Z, Ren Q, Chen L, Fang X

International Journal of Nanomedicine 2013, 8:1463-1476

Published Date: 16 April 2013

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]

Tsumura T, Yoshikawa K, Suzumura H, Kimura T, Sasaki S, Kimura I, Takeda R

Clinical Ophthalmology 2013, 7:129-130

Published Date: 16 January 2013

Cannabinoid derivate-loaded PLGA nanocarriers for oral administration: formulation, characterization, and cytotoxicity studies

Martín-Banderas L, Álvarez-Fuentes J, Durán-Lobato M, Prados J, Melguizo C, Fernández-Arévalo M, Holgado MÁ

International Journal of Nanomedicine 2012, 7:5793-5806

Published Date: 23 November 2012

Development of a nanoporous and multilayer drug-delivery platform for medical implants

Karagkiozaki V, Vavoulidis E, Karagiannidis PG, Gioti M, Fatouros DG, Vizirianakis IS, Logothetidis S

International Journal of Nanomedicine 2012, 7:5327-5338

Published Date: 8 October 2012

Modification of polyethylene glycol onto solid lipid nanoparticles encapsulating a novel chemotherapeutic agent (PK-L4) to enhance solubility for injection delivery

Fang YP, Wu PC, Huang YB, Tzeng CC, Chen YL, Hung YH, Tsai MJ, Tsai YH

International Journal of Nanomedicine 2012, 7:4995-5005

Published Date: 17 September 2012